MARKET

NVCR

NVCR

Novocure
NASDAQ
15.63
+0.99
+6.76%
After Hours: 15.56 -0.07 -0.45% 19:42 03/28 EDT
OPEN
14.55
PREV CLOSE
14.64
HIGH
16.05
LOW
14.38
VOLUME
2.81M
TURNOVER
0
52 WEEK HIGH
83.60
52 WEEK LOW
10.87
MARKET CAP
1.67B
P/E (TTM)
-8.0314
1D
5D
1M
3M
1Y
5Y
Why Novocure Stock Is Jumping Today
Shares of Novocure jumped 6.3% on Thursday. The company announced results from a phase 3 study in treating patients with brain metastases from non-small cell lung cancer. However, the company says key secondary endpoints of the study were not achieved. The healthcare stock has plunged more than 70% in the last year.
The Motley Fool · 21h ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 1d ago
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Argenx Se (ARGX) and NovoCure (NVCR)
TipRanks · 1d ago
NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock?
NASDAQ · 1d ago
NovoCure: Sell The METIS-Inspired Rally
NovoCure’s METIS trial met its primary endpoint but missed key secondary outcomes, casting doubt on TTFields' efficacy in NSCLC. Despite hitting the primary endpoint, the company's role in treatment is questionable without significant overall survival benefits. NovoCure's financial health shows a steady cash runway despite declining revenues and increasing net losses. The company's stock has rallied 15% since the release of phase 3 METIS data.
Seeking Alpha · 1d ago
Peeling Back The Layers: Exploring NovoCure Through Analyst Insights
5 analysts have shared their evaluations of NovoCure (NASDAQ:NVCR) over the past three months. The company's business involves the development of Tumor Treating Fields for the treatment of solid tumor cancers. The 12-month price targets assessed by analysts have an average target of $20.0 and a high estimate of $24.00. Novocure Ltd serves in the healthcare sector of the US.
Benzinga · 1d ago
Novocure’s stock surges after positive results in brain-cancer trial
MarketWatch · 1d ago
Novocure Is Maintained at Neutral by HC Wainwright & Co.
Dow Jones · 1d ago
More
About NVCR
NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Webull offers Novocure Ltd stock information, including NASDAQ: NVCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVCR stock methods without spending real money on the virtual paper trading platform.